Pharma Stocks
-
Reviewing Valuation After 46% Three-Month Share Price Surge
Centessa Pharmaceuticals (CNTA) stock has quietly gained steam over the past quarter, delivering a 46% climb in that time. Investors…
Read More » -
Could Caristo Collaboration Reveal NewAmsterdam Pharma’s (NAMS) Real Edge in Cardiovascular Innovation?
Caristo Diagnostics recently announced its selection as the worldwide imaging core lab for NewAmsterdam Pharma’s global REMBRANDT Cardiovascular Imaging Trial,…
Read More » -
Investors in Ajanta Pharma (NSE:AJANTPHARM) have seen impressive returns of 138% over the past five years
While Ajanta Pharma Limited (NSE:AJANTPHARM) shareholders are probably generally happy, the stock hasn’t had particularly good run recently, with the…
Read More » -
Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals
Recursion Pharmaceuticals (NASDAQ: RXRX) is a Salt Lake City–based clinical-stage “TechBio” biotech that uses AI, automation and massive biological datasets…
Read More » -
Does Harrow’s (HROW) Debt Refinancing and Melt Pharma Deal Shift Its Long-Term Growth Trajectory?
Harrow recently completed a debt refinancing, announced plans to acquire Melt Pharmaceuticals, and updated its peak sales projections, highlighting continued…
Read More » -
Rubicon Research share price dips after strong listing. Should investors buy, sell or hold this pharma stock?
Rubicon Research share price dipped over 1% on Thursday’s session after strong listing on the Indian stock market today. At…
Read More » -
Baxter International (BAX): Exploring Valuation After Collaboration With Celerity Pharmaceuticals in Healthcare Expansion
Baxter International (BAX) is drawing fresh attention after announcing a collaboration with Celerity Pharmaceuticals targeting acute care generics and oncolytic…
Read More » -
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice
Momentum investing revolves around the idea of following a stock’s recent trend in either direction. In “long context,” investors will…
Read More » -
SciSparc Enters Agreement to Transfer $11.6M Pharma Portfolio
SciSparc (Nasdaq: SPRC) entered a definitive asset-and-share purchase agreement dated October 9,…
Read More » -
Here’s Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering ‘the next big thing’, even if that means buying ‘story stocks’…
Read More »